

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-19. (Cancelled)

20. (Currently Amended) A pharmaceutical composition for treating enteric infections of *Candida albicans* in humans comprising IgY that originates from an egg of a bird hyperimmunised with *Enterobacter cloacae*.

21. (Previously Presented) The pharmaceutical composition according to claim 20, wherein the pharmaceutical composition is formulated as a freeze dried or lyophilised powder, a solution, an emulsion, a lozenge, a tablet or as a capsule together with any other pharmaceutically acceptable carrier or diluent.

22. (Previously Presented) The pharmaceutical composition according to claim 21, wherein the pharmaceutical further comprises a buffering agent.

23. (Previously Presented) The pharmaceutical composition according to claim 21, further comprising a nutritional agent.

24. (Previously Presented) The pharmaceutical composition according to claim 22, wherein the buffering agent is human breast milk or a substitute therefore.

25. (Withdrawn) A method of prophylaxis or treatment of enteric infections in newborn infants, prematurely born infants, infants having an immature immune system, patients suffering from temporary immunodeficiency and immunodeficiency diseases such as AIDS, comprising the step of:
-administering to said infant or patient a pharmaceutical composition comprising IgY that originates from an egg of a bird hyperimmunised with a microbe.

26. (Withdrawn) The method according to claim 25, wherein the infection is a bacterial infection.

27. (Withdrawn) The method according to claim 25, wherein the microbe is a bacterium, virus, fungus or parasite.

28. (Withdrawn) The method according to claim 25, wherein the microbe is *Enterobacter cloacae*.

29. (Withdrawn) The method according to claim 25, further comprising formulating the pharmaceutical composition as a freeze dried or lyophilised powder, a solution, an emulsion, a lozenge, a tablet or as a capsule or administering it together with any other pharmaceutically acceptable carrier or diluent.

30. (Withdrawn) The method according to claim 25, wherein the pharmaceutical composition is administered together with a nutritional agent.

31. (Withdrawn) The method according to claim 30, wherein the nutritional agent is human breast milk or a substitute therefore.

32. (Withdrawn) The method according to claim 25, wherein the pharmaceutical composition is administered together with a buffering agent.

33. (Withdrawn) The method according to claim 32, wherein the buffering agent is human breast milk or a substitute therefore.

34. (Withdrawn) The method according to claim 25, wherein the pharmaceutical composition is administered to newborn infants having an immature immune system.

35. (Withdrawn) The method according to claim 25, wherein the pharmaceutical composition is administered to newborn infants having a weight below 2500g.

36. (Withdrawn) The method according to claim 25, wherein the pharmaceutical composition is administered to prematurely born infants.

37. (Withdrawn) The method according to claim 25, wherein the pharmaceutical composition is administered to newborn infants having a pH above 1,5 in their stomach.

38. (Withdrawn) The method according to claim 25, wherein the pharmaceutical composition is administered to newborn infants having pH between 1,5 and 4 in their stomach.

39. (Previously Presented) The pharmaceutical composition according to claim 23, wherein the nutritional agent is human breast milk or a substitute therefore.

40. (Previously Presented) The pharmaceutical composition according to claim 23, wherein the nutritional agent is human breast milk or a substitute therefore.

41. (Cancelled)